Sinovac Wins Beijing Public Health Bureau's Bid to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens
BEIJING, Aug. 28 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE:
SVA -
News), a leading provider of biopharmaceutical products in China, announced today that the Beijing Public Health Bureau has selected Sinovac as one of the four manufacturers to supply Anflu®, Sinovac's seasonal influenza vaccine, for the benefit of the citizens of Beijing. The Beijing Public Health Bureau completed the bidding process for the purchase of flu vaccines and corresponding services for 2009 on August 26, 2009. The agreement will be executed after the public notice period.
In order to prevent and control infectious disease and to avoid contracting both the seasonal flu virus and the H1N1 virus, 2.8 million Beijing citizens will receive free inoculations against the seasonal influenza. Under the Bureau's plan, people over the age of 60, as well as elementary and secondary school students, will be inoculated with the influenza vaccine at no charge. Previously, school students were inoculated with the influenza vaccine at a charge of 20 RMB per person with allowances from the Bureau.
Mr. Weidong Yin, Chairman, President and CEO of Sinovac, commented, "As part of our mission to develop vaccines to combat the spread of disease in China and around the world, we are pleased to again be among the seasonal flu suppliers to the Beijing government. We are confident of our flexibility to be able to fill large seasonal flu vaccine orders while also executing the R&D and large-scale production of our H1N1 vaccine. Our ability to produce multiple sophisticated and high-quality vaccines simultaneously is further proof that Sinovac is a leading vaccine provider."
Developed and manufactured by Sinovac, Anflu is the only split influenza vaccine produced in China without preservatives. Over the past two years, the Company has expanded its manufacturing capacity for seasonal influenza vaccine to five million doses per year, and the same production line can produce 20 million doses of pandemic influenza vaccine, using a grant from China's National Development and Reform Commission.
In other news, Sinovac recently reported top-line preliminary results of H1N1 vaccine clinical trials. The results show the H1N1 vaccine developed by Sinovac is quite safe and has a good immunogenicity profile.
About Sinovac
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's vaccine products include Healive® (hepatitis A), Bilive® (combined hepatitis A and B), and Anflu® (influenza). Panflu(TM), Sinovac's pandemic influenza vaccine (H5N1), has already been approved for government stockpiling. Sinovac is developing vaccines for enterovirus 71, universal pandemic influenza, Japanese encephalitis, and human rabies. Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for independently developed inactivated animal rabies vaccines.
Safe Harbor Statement
This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.
For more information, please contact:
Helen G. Yang
Sinovac Biotech Ltd.
Tel: +86-10-8289-0088 x9871
Fax: +86-10-6296-6910
Investors:
Amy Glynn/Sara Pellegrino
The Ruth Group
Tel: +1-646-536-7023/7002
Media:
Janine McCargo
The Ruth Group
Tel: +1-646-536-7033
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.
SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, and mumps.
The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and was commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.
SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.
SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.
For more information, please see the Company’s website at www.sinovac.com.
Contact:
Sinovac Biotech Ltd.
PR Team
pr@sinovac.com
EN
